Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0068 | 0.6693 | 0.8343 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.4897 | 0.5292 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0.0808 | 0.5 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0851 | 0.0739 |
Echinococcus granulosus | tar DNA binding protein | 0.0068 | 0.6693 | 0.9087 |
Schistosoma mansoni | tar DNA-binding protein | 0.0068 | 0.6693 | 0.8343 |
Schistosoma mansoni | tar DNA-binding protein | 0.0068 | 0.6693 | 0.8343 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0851 | 0.0679 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0068 | 0.6693 | 0.8343 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7956 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0.0808 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0068 | 0.6693 | 0.6402 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Loa Loa (eye worm) | RNA binding protein | 0.0068 | 0.6693 | 0.7232 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4897 | 0.6521 |
Echinococcus multilocularis | tar DNA binding protein | 0.0068 | 0.6693 | 0.9087 |
Loa Loa (eye worm) | TAR-binding protein | 0.0068 | 0.6693 | 0.7232 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4024 | 0.4348 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.7332 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.0808 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0068 | 0.6693 | 0.7232 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0518 | 0.0242 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.0808 | 0.5 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.1264 | 0.0496 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3611 | 0.3902 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.0808 | 0.0873 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4897 | 0.5987 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4897 | 0.5987 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4897 | 0.6521 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.4897 | 0.4448 |
Brugia malayi | TAR-binding protein | 0.0068 | 0.6693 | 0.6402 |
Brugia malayi | RNA binding protein | 0.0068 | 0.6693 | 0.6402 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9254 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0027 | 0.0808 | 0.5 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0518 | 0.0559 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.4897 | 0.6521 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4357 | 0.4709 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.0808 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0.0808 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.0808 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3599 | 0.3036 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3186 | 0.4076 |
Schistosoma mansoni | tar DNA-binding protein | 0.0068 | 0.6693 | 0.8343 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.4897 | 0.5987 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0851 | 0.0739 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.4897 | 0.6521 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 7.9433 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.5113 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.